Skip to main content
SpringerLink
Log in

Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Townsend MJ, Monroe JG, Chan AC (2010) B-cell targeted therapies in human autoimmune diseases: an update perspective. Immunol Rev 237:264–283

    Article  PubMed  CAS  Google Scholar 

  2. Stasi R, Cooper N, Del Poeta G et al (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112:1147–1150

    Article  PubMed  CAS  Google Scholar 

  3. Sfikakis PP, Souliotis VL, Fragiadaki KG et al (2007) Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 123:66–73

    Article  PubMed  CAS  Google Scholar 

  4. Fattorossi A, Battaglia A, Buzzonetti A et al (2005) Circulating and thymic CD4+ CD25+ T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 116:134–141

    Article  PubMed  CAS  Google Scholar 

  5. Thiruppathi M, Rowin J, Li Jiang Q et al (2012) Functional defect in regulatory T cells in myasthenia gravis. Ann NY Acad Sci 1274:68–76

    Article  PubMed  CAS  Google Scholar 

  6. Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475–490

    Article  PubMed  CAS  Google Scholar 

  7. Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM (2011) Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 4:259–266

    Article  PubMed  CAS  Google Scholar 

  8. Díaz-Manera J, Martínez-Hernández E, Querol L et al (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78:189–193

    Article  PubMed  Google Scholar 

  9. Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23

    Article  PubMed  Google Scholar 

  10. Battaglia A, Buzzonetti A, Baranello C et al (2012) IL-21 synergises with IL-2 to enhance TCR-β-induced human T cell proliferation and counteracts IL-2/TGF-β induced regulatory T cell development. Immunology 139:109–120

    Article  Google Scholar 

  11. Fattorossi A, Battaglia A, Ferrandina G et al (2004) Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. Cancer 100:1418–1428

    Article  PubMed  CAS  Google Scholar 

  12. Khosroshahi A, Bloch DB, Deshpande V, Stone JH (2010) Rituximab therapy leads to rapid decline of serum IgG4 levels and prompts clinical improvement in IgG4-related systemic disease. Arthritis Rheum 62:1755–1762

    Article  PubMed  CAS  Google Scholar 

  13. Lund FE, Randall TD (2010) Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol 10:236–247

    Article  PubMed  CAS  Google Scholar 

  14. Baran J, Kowalczyk D, Ozóg M, Zembala M (2001) Three-color flow cytometry detection of intracellular cytokines in peripheral blood mononuclear cells: comparative analysis of phorbol myristate acetate-ionomycin and phytohemagglutinin stimulation. Clin Diagn Lab Immunol 8:303–313

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by a Catholic University grant (linea D.1) to A.E.

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical standard

The Ethics Committee approved the off-label use of rituximab, the clinical and laboratory exams and the related study on 05/04/2011 (Protocol: P/237/CS/2011).

Author information

Authors and Affiliations

  1. Laboratory of Immunology, Department of Obstetrics and Gynaecology, Catholic University, Rome, Italy

    Valentina Catzola, Alessandra Battaglia, Alexia Buzzonetti, Marco Fossati & Andrea Fattorossi

  2. Institute of General Pathology, Catholic University, Rome, Italy

    Flavia Scuderi

  3. Institute of Neurology, Catholic University, L.go A. Gemelli 8, 00168, Rome, Italy

    Amelia Evoli

Authors
  1. Valentina Catzola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandra Battaglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexia Buzzonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marco Fossati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Flavia Scuderi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrea Fattorossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Amelia Evoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amelia Evoli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Catzola, V., Battaglia, A., Buzzonetti, A. et al. Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. J Neurol 260, 2163–2165 (2013). https://doi.org/10.1007/s00415-013-6987-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-013-6987-y

Keywords

Search

Navigation